Generic placeholder image

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials

Author(s): Ronan J. Kelly, Ariel Lopez-Chavez and Eva Szabo

Volume 12, Issue 13, 2011

Page: [1983 - 1988] Pages: 6

DOI: 10.2174/138945011798184173

Price: $65

Abstract

Preclinical models and data from clinical trials suggest that cancer is a preventable disease. However, demonstration of a preventive effect requires large phase III clinical trials of long duration and involves many thousands of participants. The decision to proceed with phase III studies therefore must be informed by robust efficacy and safety data. This requires a systematic review of all available preclinical, epidemiological, and clinical data, along with a mechanistic understanding of the biology of the disease under study. In this review we identify the issues that are critical to decision-making prior to embarking on late phase prevention clinical trials and provide a framework for making such decisions.

Keywords: cancer, chemoprevention, clinical trials, carcinogenesis, efficacy, EGFR, safety, oncologic, phase III trials, NSAID


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy